These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 17220786

  • 1. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.
    Ghofaili KA, Fung M, Ao Z, Meloche M, Shapiro RJ, Warnock GL, Elahi D, Meneilly GS, Thompson DM.
    Transplantation; 2007 Jan 15; 83(1):24-8. PubMed ID: 17220786
    [Abstract] [Full Text] [Related]

  • 2. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA, Kane MP, Busch RS.
    Pharmacotherapy; 2007 Oct 15; 27(10):1449-55. PubMed ID: 17896900
    [Abstract] [Full Text] [Related]

  • 3. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.
    Taylor K, Kim D, Nielsen LL, Aisporna M, Baron AD, Fineman MS.
    Horm Metab Res; 2005 Oct 15; 37(10):627-32. PubMed ID: 16278786
    [Abstract] [Full Text] [Related]

  • 4. Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs best medical therapy in type 1 diabetes mellitus.
    Warnock GL, Meloche RM, Thompson D, Shapiro RJ, Fung M, Ao Z, Ho S, He Z, Dai LJ, Young L, Blackburn L, Kozak S, Kim PT, Al-Adra D, Johnson JD, Liao YH, Elliott T, Verchere CB.
    Arch Surg; 2005 Aug 15; 140(8):735-44. PubMed ID: 16103282
    [Abstract] [Full Text] [Related]

  • 5. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL, Ratner RE, Kim DD, Qu Y, Fechner LL, Lenox SM, Holcombe JH.
    Clin Ther; 2008 May 15; 30(5):858-67. PubMed ID: 18555933
    [Abstract] [Full Text] [Related]

  • 6. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
    Linnebjerg H, Kothare PA, Skrivanek Z, de la Peña A, Atkins M, Ernest CS, Trautmann ME.
    Diabet Med; 2006 Mar 15; 23(3):240-5. PubMed ID: 16492205
    [Abstract] [Full Text] [Related]

  • 7. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
    Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K.
    Diabetes Care; 2007 Jun 15; 30(6):1487-93. PubMed ID: 17353504
    [Abstract] [Full Text] [Related]

  • 8. Insulin independence of unstable diabetic patient after single living donor islet transplantation.
    Matsumoto S, Okitsu T, Iwanaga Y, Noguchi H, Nagata H, Yonekawa Y, Yamada Y, Nakai Y, Ueda M, Ishii A, Yabunaka E, Shapiro JA, Tanaka K.
    Transplant Proc; 2005 Oct 15; 37(8):3427-9. PubMed ID: 16298617
    [Abstract] [Full Text] [Related]

  • 9. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
    Gallwitz B.
    Int J Clin Pract; 2006 Dec 15; 60(12):1654-61. PubMed ID: 17109672
    [Abstract] [Full Text] [Related]

  • 10. Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus.
    Paisley AN, Savage MW, Wiles PG.
    Diabet Med; 2009 Sep 15; 26(9):935-8. PubMed ID: 19719716
    [Abstract] [Full Text] [Related]

  • 11. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects.
    Froud T, Faradji RN, Pileggi A, Messinger S, Baidal DA, Ponte GM, Cure PE, Monroy K, Mendez A, Selvaggi G, Ricordi C, Alejandro R.
    Transplantation; 2008 Jul 15; 86(1):36-45. PubMed ID: 18622276
    [Abstract] [Full Text] [Related]

  • 12. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
    Mari A, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E, Halseth A.
    Horm Metab Res; 2006 Dec 15; 38(12):838-44. PubMed ID: 17163361
    [Abstract] [Full Text] [Related]

  • 13. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
    Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, Musi N, DeFronzo RA, Cersosimo E.
    Am J Physiol Endocrinol Metab; 2008 May 15; 294(5):E846-52. PubMed ID: 18334612
    [Abstract] [Full Text] [Related]

  • 14. Effect of glucagon-like peptide-1 (7-37) on beta-cell function after islet transplantation in type 1 diabetes.
    Fung M, Thompson D, Shapiro RJ, Warnock GL, Andersen DK, Elahi D, Meneilly GS.
    Diabetes Res Clin Pract; 2006 Nov 15; 74(2):189-93. PubMed ID: 16621111
    [Abstract] [Full Text] [Related]

  • 15. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, Smith PA, Gedulin BR, Flanagan SD, Jodka CM, Hoyt JA, McCowen KM, Parkes DG, Anderson CM.
    Regul Pept; 2007 Jun 07; 141(1-3):113-9. PubMed ID: 17292977
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.
    Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD.
    Diabetes Metab Res Rev; 2004 Jun 07; 20(5):411-7. PubMed ID: 15343588
    [Abstract] [Full Text] [Related]

  • 17. Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success.
    Koh A, Senior P, Salam A, Kin T, Imes S, Dinyari P, Malcolm A, Toso C, Nilsson B, Korsgren O, Shapiro AM.
    Transplantation; 2010 Feb 27; 89(4):465-71. PubMed ID: 20177350
    [Abstract] [Full Text] [Related]

  • 18. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.
    Segal JB, Dy SM, Millman EA, Herbert R, Bass EB, Wu A.
    Clin Ther; 2007 Aug 27; 29(8):1784-94. PubMed ID: 17919559
    [Abstract] [Full Text] [Related]

  • 19. Pancreas islet transplantation in patients with type 1 diabetes mellitus after kidney transplantation.
    Gonzalez Molina M, Alonso A, Briones R, Fernandez N, Caballero A, Miranda JM, Navarro A, Castro MJ, Burgos D, Cabello M, Sola E, Escaño A, Muñoz J.
    Transplant Proc; 2005 Apr 27; 37(3):1443-5. PubMed ID: 15866632
    [Abstract] [Full Text] [Related]

  • 20. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA).
    Zhou Z, Li X, Huang G, Peng J, Yang L, Yan X, Wang J.
    Diabetes Metab Res Rev; 2005 Apr 27; 21(2):203-8. PubMed ID: 15386806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.